Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
RespireRx Pharmaceuticals Inc. (RSPI) generates news primarily through research, clinical development, regulatory and capital markets activities related to its neuromodulator and pharmaceutical cannabinoid programs. Through the RespireRx Group, which includes EndeavourRx LLC and ResolutionRx Ltd, the company reports progress on drug candidates targeting epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from spinal cord injury (SCI), certain neurological orphan diseases and obstructive sleep apnea (OSA).
News updates often highlight preclinical and translational findings for the company’s lead compounds. For example, RespireRx has reported peer-reviewed publications demonstrating that its AMPAkine CX1739 improved bladder function in rodent models of spinal cord injury and that KRM-II-81, its lead GABAkine, suppressed epileptiform activity in human brain tissue slices from a pharmaco-resistant epilepsy patient. Additional releases describe KRM-II-81’s advancement within the NIH HEAL Initiative Preclinical Screening Platform for Pain, where it has shown anti-pain effects in animal models at doses with minimal or no detectable side effects.
Investors and observers can also find announcements about external funding and collaborations, such as a Department of Defense translational research award to Shirley Ryan AbilityLab for a Phase 2A/2B clinical trial of CX1739 in SCI patients and an NIH/NINDS Small Business Innovation Research (SBIR) grant to support IND-enabling work for KRM-II-81 in epilepsy. Company communications further cover strategic steps at ResolutionRx Ltd to advance a new dronabinol formulation for OSA, including use of the Australian R&D Tax Incentive and plans for stock exchange listings.
Regulatory and corporate developments are another key theme in RSPI news. RespireRx has issued releases about SEC correspondence, the Section 12(j) order revoking registration of its securities, and its stated intention to pursue future Form 10 registration. Capital-raising initiatives, including a Regulation D, Rule 506(c) private placement across RespireRx, EndeavourRx and ResolutionRx, are also described. For ongoing context on RSPI, readers can review this news stream for updates on clinical plans, grant awards, licensing agreements, governance changes and the company’s responses to regulatory actions.
RespireRx Pharmaceuticals (OTCQ:RSPI) reviews its progress over the past year and outlines future plans. The company aims to unlock value through restructuring and two key platforms: pharmaceutical cannabinoids and neuromodulators. Recent achievements include successful trials with dronabinol for obstructive sleep apnea and advancements in AMPAkines and GABAkines for spinal cord injury and epilepsy treatments. However, financing challenges persist, particularly with the stock below the $0.02 offering price set for up to $7.5 million. Leadership changes were also noted, with Dr. Arnold Lippa stepping in as Interim CEO.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) has announced the publication of a manuscript detailing the pharmacology of its compound KRM-II-81, marking a significant advancement in developing GABAkines for neurological and psychiatric disorders. The paper describes KRM-II-81's efficacy against pharmacoresistant epilepsy and neuropathic pain, showcasing its low sedation effects and lack of tolerance development. The company's leadership sees potential in KRM-II-81 as a breakthrough treatment, moving towards IND enabling studies to address significant unmet medical needs.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announces participation in two upcoming investor conferences. CFO Jeff Margolis will present live at the Life Sciences Virtual Investor Conference on December 16, 2021, discussing the company’s vision and programs. Concurrently, President and CEO Tim Jones will present a pre-recorded video at the Biotech Showcase from January 17-19, 2022. These platforms offer insights into RespireRx's innovative treatments for psychiatric and neurological disorders, including obstructive sleep apnea and ADHD.
RespireRx Pharmaceuticals (OTCQB: RSPI) has published a pivotal review article on GABAkines, focusing on the development of positive allosteric modulators of GABAA receptors. This article highlights the potential of KRM-II-81, a GABAkine in development, to treat epilepsy and pain with reduced side effects compared to traditional benzodiazepines. KRM-II-81 shows promise in preclinical studies, demonstrating high anti-convulsant and analgesic activities without the risks of tolerance or dependence. The findings strongly support advancements in treatment options for neurological disorders.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the publication of research on KRM-II-81, a novel analgesic, in the book The Neurobiology, Physiology, and Psychology of Pain. This compound selectively potentiates GABAA receptors, showing significant analgesic efficacy without common opioid side effects. KRM-II-81 demonstrated comparable or superior analgesic effects in animal models compared to traditional analgesics, while avoiding tolerance, dependence, and respiratory depression. The company is optimistic about KRM-II-81's potential to address pain management amidst the opioid crisis.
RespireRx Pharmaceuticals (OTCQB: RSPI) announced two significant peer-reviewed studies led by Dr. David Fuller, demonstrating the potential of AMPAkines CX1739 and CX717 to enhance motor nerve activity and muscle function in spinal cord injury models. The first study highlights CX717's effectiveness in increasing motor output in rats, while the second showcases improvements in diaphragm activity and overall motor functioning in awake rats post-spinal injury. These findings bolster hopes for AMPAkines as therapeutic alternatives for spinal cord injury recovery, paving the path toward human clinical trials.
On November 22, 2021, RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the availability of a podcast featuring CEO Timothy Jones. Recorded on October 21, 2021, and released by OTC Markets on November 17, 2021, the podcast discusses the company's business units, including pharmaceutical cannabinoids and neuromodulators, along with targeted therapeutic indications such as Obstructive Sleep Apnea and ADHD. Notably, potential offerings pursuant to Regulation A were not discussed. The company emphasizes its commitment to addressing unmet medical needs through innovative therapies.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) has released a video interview featuring CFO Jeff Margolis, providing insights into the company's structure, programs, and market opportunities. The interview is accessible to the public on November 4, 2021, via ProActive Investors and RespireRx's website. Margolis discussed the upcoming Regulation A offering and the preliminary offering amount of 250 million shares priced between $0.02 and $0.03 per share, aiming for a maximum raise of $7.5 million. This offering is pending SEC qualification.
RespireRx Pharmaceuticals (OTCQB: RSPI) will participate in the Access China Biotech 2021 Digital conference from June 9-14, 2021. This event facilitates connections between Western pharmaceutical and biotech leaders and Chinese companies. RespireRx focuses on developing treatments for neurological disorders, specifically targeting conditions like obstructive sleep apnea and ADHD. The company aims to advance its innovative drug candidates based on cannabinoids and neuromodulators. Their corporate presentation is available online for stakeholders.
RespireRx Pharmaceuticals (OTCQB: RSPI) announces a significant advancement in spinal cord injury treatment. At the Annual Experimental Biology Conference, researchers presented findings demonstrating that low doses of AMPAkines CX717 and CX1739 effectively increase diaphragm activity and tidal volume in non-anesthetized rats post-cervical spinal cord injury. The ongoing collaboration with the University of Florida is focused on developing a Phase 2 clinical trial aimed at restoring motor functions in patients with spinal cord injury. This research highlights the potential of AMPAkines as a groundbreaking treatment option.